Peripheral and Central Sites of Action for the Non-selective Cannabinoid Agonist WIN 55,212-2 in a Rat Model of Post-operative Pain

Overview

Journal Br J Pharmacol

Publisher Wiley

Specialty Pharmacology

Date 2009 Apr 18

PMID 19371344

Citations 5

Authors

C Z Zhu

J P Mikusa

Y Fan

P R Hollingsworth

M Pai

P Chandran

A V Daza

B B Yao

M J Dart

M D Meyer

M W Decker

G C Hsieh

P Honore

Affiliations

Soon will be listed here.

Abstract

Background And Purpose: Activation of cannabinoid (CB) receptors decreases nociceptive transmission in inflammatory or neuropathic pain states. However, the effects of CB receptor agonists in post-operative pain remain to be investigated. Here, we characterized the anti-allodynic effects of WIN 55,212-2 (WIN) in a rat model of post-operative pain.

Experimental Approach: WIN 55,212-2 was characterized in radioligand binding and in vitro functional assays at rat and human CB(1) and CB(2) receptors. Analgesic activity and site(s) of action of WIN were assessed in the skin incision-induced post-operative pain model in rats; receptor specificity was investigated using selective CB(1) and CB(2) receptor antagonists.

Key Results: WIN 55,212-2 exhibited non-selective affinity and agonist efficacy at human and rat CB(1) versus CB(2) receptors. Systemic administration of WIN decreased injury-induced mechanical allodynia and these effects were reversed by pretreatment with a CB(1) receptor antagonist, but not with a CB(2) receptor antagonist, given by systemic, intrathecal and supraspinal routes. In addition, peripheral administration of both CB(1) and CB(2) antagonists blocked systemic WIN-induced analgesic activity.

Conclusions And Implications: Both CB(1) and CB(2) receptors were involved in the peripheral anti-allodynic effect of systemic WIN in a pre-clinical model of post-operative pain. In contrast, the centrally mediated anti-allodynic activity of systemic WIN is mostly due to the activation of CB(1) but not CB(2) receptors at both the spinal cord and brain levels. However, the increased potency of WIN following i.c.v. administration suggests that its main site of action is at CB(1) receptors in the brain.

Citing Articles

Prevalence of Cannabinoid (CBD) Use in Orthopaedic Sports Medicine Patients.

Deckey D, Doan M, Hassebrock J, Patel K, Economopoulos K, Tokish J Orthop J Sports Med. 2022; 10(4):23259671221087629.

PMID: 35400139 PMC: 8988677. DOI: 10.1177/23259671221087629.

Activation of cannabinoid CB1 receptor contributes to suppression of spinal nociceptive transmission and inhibition of mechanical hypersensitivity by Aβ-fiber stimulation.

Yang F, Xu Q, Shu B, Tiwari V, He S, Vera-Portocarrero L Pain. 2016; 157(11):2582-2593.

PMID: 27589093 PMC: 5069149. DOI: 10.1097/j.pain.0000000000000680.

Centrally mediated antinociceptive effects of cannabinoid receptor ligands in rat models of nociception.

Hama A, Sagen J Pharmacol Biochem Behav. 2011; 100(2):340-6.

PMID: 21958947 PMC: 3199362. DOI: 10.1016/j.pbb.2011.09.004.

Activation of spinal and supraspinal cannabinoid-1 receptors leads to antinociception in a rat model of neuropathic spinal cord injury pain.

Hama A, Sagen J Brain Res. 2011; 1412:44-54.

PMID: 21813113 PMC: 3159760. DOI: 10.1016/j.brainres.2011.07.031.

Local activation of cannabinoid CB₁ receptors in the urinary bladder reduces the inflammation-induced sensitization of bladder afferents.

Walczak J, Cervero F Mol Pain. 2011; 7:31.

PMID: 21554718 PMC: 3115893. DOI: 10.1186/1744-8069-7-31.

References

Yaksh T, Rudy T . Chronic catheterization of the spinal subarachnoid space. Physiol Behav. 1976; 17(6):1031-6. DOI: 10.1016/0031-9384(76)90029-9. View

Piomelli D . The endocannabinoid system: a drug discovery perspective. Curr Opin Investig Drugs. 2005; 6(7):672-9. View

TSOU K, Brown S, Mackie K, Walker J . Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience. 1998; 83(2):393-411. DOI: 10.1016/s0306-4522(97)00436-3. View

Kukushkin M, Igonkina S, Churyukanov M, Churyukanov V, Bobrov M, Bezuglov V . Role of cannabinoid receptor agonists in mechanisms of suppression of central pain syndrome. Bull Exp Biol Med. 2007; 142(1):39-42. DOI: 10.1007/s10517-006-0286-x. View

Costa B, Colleoni M, Conti S, Trovato A, Bianchi M, Sotgiu M . Repeated treatment with the synthetic cannabinoid WIN 55,212-2 reduces both hyperalgesia and production of pronociceptive mediators in a rat model of neuropathic pain. Br J Pharmacol. 2003; 141(1):4-8. PMC: 1574173. DOI: 10.1038/sj.bjp.0705587. View

Fox A, Kesingland A, Gentry C, McNair K, Patel S, Urban L . The role of central and peripheral Cannabinoid1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain. Pain. 2001; 92(1-2):91-100. DOI: 10.1016/s0304-3959(00)00474-7. View

Farquhar-Smith W, Rice A . A novel neuroimmune mechanism in cannabinoid-mediated attenuation of nerve growth factor-induced hyperalgesia. Anesthesiology. 2003; 99(6):1391-401. DOI: 10.1097/00000542-200312000-00024. View

Yesilyurt O, Dogrul A, Gul H, Seyrek M, Kusmez O, Ozkan Y . Topical cannabinoid enhances topical morphine antinociception. Pain. 2003; 105(1-2):303-8. DOI: 10.1016/s0304-3959(03)00245-8. View

Hama A, Sagen J . Antinociceptive effect of cannabinoid agonist WIN 55,212-2 in rats with a spinal cord injury. Exp Neurol. 2006; 204(1):454-7. PMC: 1861843. DOI: 10.1016/j.expneurol.2006.09.002. View

10.

Raffa R, Stone Jr D, Hipp S . Differential cholera-toxin sensitivity of supraspinal antinociception induced by the cannabinoid agonists delta9-THC, WIN 55,212-2 and anandamide in mice. Neurosci Lett. 1999; 263(1):29-32. DOI: 10.1016/s0304-3940(99)00096-8. View

11.

TSOU K, Lowitz K, Hohmann A, Martin W, Hathaway C, Bereiter D . Suppression of noxious stimulus-evoked expression of Fos protein-like immunoreactivity in rat spinal cord by a selective cannabinoid agonist. Neuroscience. 1996; 70(3):791-8. DOI: 10.1016/s0306-4522(96)83015-6. View

12.

Yao B, Mukherjee S, Fan Y, Garrison T, Daza A, Grayson G . In vitro pharmacological characterization of AM1241: a protean agonist at the cannabinoid CB2 receptor?. Br J Pharmacol. 2006; 149(2):145-54. PMC: 2013801. DOI: 10.1038/sj.bjp.0706838. View

13.

Martin W, Loo C, Basbaum A . Spinal cannabinoids are anti-allodynic in rats with persistent inflammation. Pain. 1999; 82(2):199-205. DOI: 10.1016/S0304-3959(99)00045-7. View

14.

Lim G, Sung B, Ji R, Mao J . Upregulation of spinal cannabinoid-1-receptors following nerve injury enhances the effects of Win 55,212-2 on neuropathic pain behaviors in rats. Pain. 2003; 105(1-2):275-83. DOI: 10.1016/s0304-3959(03)00242-2. View

15.

Richardson J, Kilo S, Hargreaves K . Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors. Pain. 1998; 75(1):111-119. DOI: 10.1016/S0304-3959(97)00213-3. View

16.

Hohmann A, TSOU K, Walker J . Intrathecal cannabinoid administration suppresses noxious stimulus-evoked Fos protein-like immunoreactivity in rat spinal cord: comparison with morphine. Zhongguo Yao Li Xue Bao. 2001; 20(12):1132-6. View

17.

Labuda C, Koblish M, Little P . Cannabinoid CB2 receptor agonist activity in the hindpaw incision model of postoperative pain. Eur J Pharmacol. 2005; 527(1-3):172-4. DOI: 10.1016/j.ejphar.2005.10.020. View

18.

Yao B, Hsieh G, Frost J, Fan Y, Garrison T, Daza A . In vitro and in vivo characterization of A-796260: a selective cannabinoid CB2 receptor agonist exhibiting analgesic activity in rodent pain models. Br J Pharmacol. 2007; 153(2):390-401. PMC: 2219533. DOI: 10.1038/sj.bjp.0707568. View

19.

Lichtman A, Cook S, Martin B . Investigation of brain sites mediating cannabinoid-induced antinociception in rats: evidence supporting periaqueductal gray involvement. J Pharmacol Exp Ther. 1996; 276(2):585-93. View

20.

Johanek L, Simone D . Cannabinoid agonist, CP 55,940, prevents capsaicin-induced sensitization of spinal cord dorsal horn neurons. J Neurophysiol. 2004; 93(2):989-97. DOI: 10.1152/jn.00673.2004. View